{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:20:17Z","timestamp":1791069617834,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1124\/jpet.106.114017","type":"journal-article","created":{"date-parts":[[2007,2,9]],"date-time":"2007-02-09T01:50:30Z","timestamp":1170985830000},"page":"485-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The 5-Hydroxytryptamine2A Receptor Is Involved in (+)-Norfenfluramine-Induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension"],"prefix":"10.1016","volume":"321","author":[{"given":"Wei","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie W.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.106.114017_bib1","doi-asserted-by":"crossref","unstructured":"Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609\u2013616.","DOI":"10.1056\/NEJM199608293350901"},{"key":"10.1124\/jpet.106.114017_bib2","doi-asserted-by":"crossref","unstructured":"Banes AK and Watts SW (2002) Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension 39: 394\u2013398.","DOI":"10.1161\/hy02t2.102793"},{"key":"10.1124\/jpet.106.114017_bib3","unstructured":"Cohen ML, Schenck KW, Mabry TE, Nelson DL, and Audia JE (1996) LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Serotonin Res 3: 131\u2013144."},{"key":"10.1124\/jpet.106.114017_bib4","doi-asserted-by":"crossref","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581\u2013588.","DOI":"10.1056\/NEJM199708283370901"},{"key":"10.1124\/jpet.106.114017_bib5","doi-asserted-by":"crossref","unstructured":"Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 75\u201381.","DOI":"10.1016\/S0026-895X(24)26444-0"},{"key":"10.1124\/jpet.106.114017_bib6","doi-asserted-by":"crossref","unstructured":"Hong Z, Olschewski A, Reeve HL, Nelson DP, Hong F, and Weir EK (2004) Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol 286: L531\u2013L538.","DOI":"10.1152\/ajplung.00247.2003"},{"key":"10.1124\/jpet.106.114017_bib7","doi-asserted-by":"crossref","unstructured":"Launay JM, Herve P, Peoc\u2019h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8: 1129\u20131135.","DOI":"10.1038\/nm764"},{"key":"10.1124\/jpet.106.114017_bib8","unstructured":"Mabadeje AF (1974) Proceedings: fenfluramine-induced hypertension. West Afr J Pharmacol Drug Res 2: 54."},{"key":"10.1124\/jpet.106.114017_bib9","doi-asserted-by":"crossref","unstructured":"Michelakis ED, Weir EK, Nelson DP, Reeve HL, Tolarova S, and Archer SL (1999) Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells. J Pharmacol Exp Ther 291: 1143\u20131149.","DOI":"10.1016\/S0022-3565(24)35220-6"},{"key":"10.1124\/jpet.106.114017_bib10","doi-asserted-by":"crossref","unstructured":"Ni W, Li MW, Thakali K, Fink GD, and Watts SW (2004a) The fenfluramine metabolite (+)-norfenfluramine is vasoactive. J Pharmacol Exp Ther 309: 845\u2013852.","DOI":"10.1124\/jpet.103.060806"},{"key":"10.1124\/jpet.106.114017_bib11","doi-asserted-by":"crossref","unstructured":"Ni W, Thompson JM, Northcott CA, Lookingland K, and Watts SW (2004b) The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43: 770\u2013781.","DOI":"10.1097\/00005344-200406000-00006"},{"key":"10.1124\/jpet.106.114017_bib12","doi-asserted-by":"crossref","unstructured":"Pertz H and Eich E (1992) O- acylated lysergol and dihydrolysergol-I derivatives as competitive antagonists of 5-HT at 5-HT2 receptors of rat tail artery: allosteric modulation instead of pseudoirreversible inhibition. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 345: 394\u2013401.","DOI":"10.1007\/BF00176616"},{"key":"10.1124\/jpet.106.114017_bib13","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836\u20132841.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"10.1124\/jpet.106.114017_bib14","doi-asserted-by":"crossref","unstructured":"Smith BM, Thomsen WJ, and Grottick AJ (2006) The potential use of selective 5-HT2C agonists in treating obesity. Exp Opin Investig Drugs 15: 257\u2013266.","DOI":"10.1517\/13543784.15.3.257"},{"key":"10.1124\/jpet.106.114017_bib15","doi-asserted-by":"crossref","unstructured":"Szarek JL, Zhang JZ, and Gruetter CA (1995) Mechanisms of 5-hydroxytryptamine-induced contraction of isolated rat intrapulmonary bronchi. Pulm Pharmacol 8: 273\u2013281.","DOI":"10.1006\/pulp.1995.1037"},{"key":"10.1124\/jpet.106.114017_bib16","doi-asserted-by":"crossref","unstructured":"Watts SW, Baez M, and Webb RC (1996) The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats. J Pharmacol Exp Ther 277: 1103\u20131113.","DOI":"10.1016\/S0022-3565(25)12898-X"},{"key":"10.1124\/jpet.106.114017_bib17","doi-asserted-by":"crossref","unstructured":"Watts SW (2002) Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension 39: 825\u2013829.","DOI":"10.1161\/hy0302.104668"},{"key":"10.1124\/jpet.106.114017_bib18","doi-asserted-by":"crossref","unstructured":"Watts SW and Fink GD (1999) 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol 276: H944\u2013H952.","DOI":"10.1152\/ajpheart.1999.276.3.H944"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524338194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.106.114017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:14:38Z","timestamp":1740003278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524338194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0022356524338194"],"URL":"https:\/\/doi.org\/10.1124\/jpet.106.114017","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 5-Hydroxytryptamine2A Receptor Is Involved in (+)-Norfenfluramine-Induced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.106.114017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}